Is ESTA or GKOS more profitable?

Establishment Labs has a net margin of -19.05% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat Establishment Labs' return on equity. Company Net Margins Return on Equity Return on Assets Establishment Labs -19.05% -218.77% -12.31% Glaukos -34.34% -6.92% -5.25%

Does the media refer more to ESTA or GKOS?

In the previous week, Glaukos had 7 more articles in the media than Establishment Labs. MarketBeat recorded 10 mentions for Glaukos and 3 mentions for Establishment Labs. Glaukos' average media sentiment score of 0.75 beat Establishment Labs' score of 0.30 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, LQDA or ESTA?

Establishment Labs has higher revenue and earnings than Liquidia. Establishment Labs is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 43.77 -$68.92M $0.14 556.64 Establishment Labs $211.08M 12.27 -$51.06M -$1.49 N/A

Does the media favor LQDA or ESTA?

In the previous week, Liquidia had 7 more articles in the media than Establishment Labs. MarketBeat recorded 10 mentions for Liquidia and 3 mentions for Establishment Labs. Liquidia's average media sentiment score of 0.59 beat Establishment Labs' score of 0.30 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Establishment Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ESTA or BLCO?

In the previous week, Bausch + Lomb had 6 more articles in the media than Establishment Labs. MarketBeat recorded 9 mentions for Bausch + Lomb and 3 mentions for Establishment Labs. Bausch + Lomb's average media sentiment score of 0.56 beat Establishment Labs' score of 0.30 indicating that Bausch + Lomb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch + Lomb 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate STVN or ESTA?

Establishment Labs has a consensus price target of $89.71, indicating a potential upside of 1.91%. Given Establishment Labs' higher probable upside, analysts clearly believe Establishment Labs is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.83 Establishment Labs 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

Does the media refer more to STVN or ESTA?

In the previous week, Establishment Labs had 2 more articles in the media than Stevanato Group. MarketBeat recorded 3 mentions for Establishment Labs and 1 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 0.84 beat Establishment Labs' score of 0.30 indicating that Stevanato Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Establishment Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Establishment Labs (ESTA) Competitors

$88.03 -0.74 (-0.83%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$88.00 -0.03 (-0.03%)

As of 07/10/2026 04:10 PM Eastern

Compare

ESTA vs. GKOS, LQDA, BLCO, STVN, and LIVN

Should you buy Establishment Labs stock or one of its competitors? MarketBeat compares Establishment Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Establishment Labs include Glaukos (GKOS), Liquidia (LQDA), Bausch + Lomb (BLCO), Stevanato Group (STVN), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.

How does Establishment Labs compare to Glaukos?

Establishment Labs (NASDAQ:ESTA) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

In the previous week, Glaukos had 7 more articles in the media than Establishment Labs. MarketBeat recorded 10 mentions for Glaukos and 3 mentions for Establishment Labs. Glaukos' average media sentiment score of 0.75 beat Establishment Labs' score of 0.30 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Establishment Labs has higher earnings, but lower revenue than Glaukos. Establishment Labs is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	12.27	-$51.06M	-$1.49	N/A
Glaukos	$551.35M	16.27	-$187.69M	-$3.28	N/A

Establishment Labs currently has a consensus target price of $89.71, suggesting a potential upside of 1.91%. Glaukos has a consensus target price of $151.62, suggesting a potential downside of 0.74%. Given Establishment Labs' higher probable upside, equities analysts plainly believe Establishment Labs is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Establishment Labs has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Glaukos has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

Establishment Labs has a net margin of -19.05% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
Glaukos	-34.34%	-6.92%	-5.25%

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 10.0% of Establishment Labs shares are held by insiders. Comparatively, 5.9% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Glaukos beats Establishment Labs on 10 of the 16 factors compared between the two stocks.

How does Establishment Labs compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Establishment Labs (NASDAQ:ESTA) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Establishment Labs has higher revenue and earnings than Liquidia. Establishment Labs is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	43.77	-$68.92M	$0.14	556.64
Establishment Labs	$211.08M	12.27	-$51.06M	-$1.49	N/A

Liquidia presently has a consensus price target of $68.88, suggesting a potential downside of 11.62%. Establishment Labs has a consensus price target of $89.71, suggesting a potential upside of 1.91%. Given Establishment Labs' higher probable upside, analysts plainly believe Establishment Labs is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

64.5% of Liquidia shares are held by institutional investors. Comparatively, 72.9% of Establishment Labs shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 10.0% of Establishment Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Liquidia has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

In the previous week, Liquidia had 7 more articles in the media than Establishment Labs. MarketBeat recorded 10 mentions for Liquidia and 3 mentions for Establishment Labs. Liquidia's average media sentiment score of 0.59 beat Establishment Labs' score of 0.30 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Liquidia has a net margin of 7.74% compared to Establishment Labs' net margin of -19.05%. Liquidia's return on equity of 46.82% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
Establishment Labs	-19.05%	-218.77%	-12.31%

Summary

Liquidia beats Establishment Labs on 11 of the 17 factors compared between the two stocks.

How does Establishment Labs compare to Bausch + Lomb?

Establishment Labs (NASDAQ:ESTA) and Bausch + Lomb (NYSE:BLCO) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Establishment Labs has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

Establishment Labs presently has a consensus price target of $89.71, indicating a potential upside of 1.91%. Bausch + Lomb has a consensus price target of $18.00, indicating a potential upside of 10.84%. Given Bausch + Lomb's higher probable upside, analysts clearly believe Bausch + Lomb is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 10.0% of Establishment Labs shares are held by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bausch + Lomb has a net margin of -4.21% compared to Establishment Labs' net margin of -19.05%. Bausch + Lomb's return on equity of 3.60% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
Bausch + Lomb	-4.21%	3.60%	1.69%

In the previous week, Bausch + Lomb had 6 more articles in the media than Establishment Labs. MarketBeat recorded 9 mentions for Bausch + Lomb and 3 mentions for Establishment Labs. Bausch + Lomb's average media sentiment score of 0.56 beat Establishment Labs' score of 0.30 indicating that Bausch + Lomb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch + Lomb	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Establishment Labs has higher earnings, but lower revenue than Bausch + Lomb. Establishment Labs is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	12.27	-$51.06M	-$1.49	N/A
Bausch + Lomb	$5.10B	1.14	-$360M	-$0.62	N/A

Summary

Bausch + Lomb beats Establishment Labs on 9 of the 16 factors compared between the two stocks.

How does Establishment Labs compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Establishment Labs (NASDAQ:ESTA) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

In the previous week, Establishment Labs had 2 more articles in the media than Stevanato Group. MarketBeat recorded 3 mentions for Establishment Labs and 1 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 0.84 beat Establishment Labs' score of 0.30 indicating that Stevanato Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Stevanato Group has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

72.9% of Establishment Labs shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by insiders. Comparatively, 10.0% of Establishment Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Stevanato Group has a net margin of 11.76% compared to Establishment Labs' net margin of -19.05%. Stevanato Group's return on equity of 10.27% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	11.76%	10.27%	6.08%
Establishment Labs	-19.05%	-218.77%	-12.31%

Stevanato Group has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	4.43	€158.21M	€0.59	33.26
Establishment Labs	$211.08M	12.27	-$51.06M	-$1.49	N/A

Establishment Labs has a consensus price target of $89.71, indicating a potential upside of 1.91%. Given Establishment Labs' higher probable upside, analysts clearly believe Establishment Labs is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Stevanato Group beats Establishment Labs on 10 of the 17 factors compared between the two stocks.

How does Establishment Labs compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Establishment Labs (NASDAQ:ESTA) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Establishment Labs has lower revenue, but higher earnings than LivaNova. Establishment Labs is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.27	-$242.47M	$1.95	42.34
Establishment Labs	$211.08M	12.27	-$51.06M	-$1.49	N/A

In the previous week, Establishment Labs had 2 more articles in the media than LivaNova. MarketBeat recorded 3 mentions for Establishment Labs and 1 mentions for LivaNova. LivaNova's average media sentiment score of 1.44 beat Establishment Labs' score of 0.30 indicating that LivaNova is being referred to more favorably in the media.

Company	Overall Sentiment
LivaNova	Positive
Establishment Labs	Neutral

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 10.0% of Establishment Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

LivaNova has a net margin of 7.48% compared to Establishment Labs' net margin of -19.05%. LivaNova's return on equity of 16.48% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Establishment Labs	-19.05%	-218.77%	-12.31%

LivaNova presently has a consensus target price of $80.75, indicating a potential downside of 2.19%. Establishment Labs has a consensus target price of $89.71, indicating a potential upside of 1.91%. Given Establishment Labs' stronger consensus rating and higher probable upside, analysts plainly believe Establishment Labs is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

LivaNova has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Summary

LivaNova and Establishment Labs tied by winning 8 of the 16 factors compared between the two stocks.

Get Establishment Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ESTA vs. The Competition

Export

Metric	Establishment Labs	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.61B	$9.59B	$7.14B	$12.64B
Dividend Yield	N/A	1.63%	2.68%	7.83%
P/E Ratio	-59.08	26.41	27.42	24.58
Price / Sales	12.27	18.14	593.42	121.59
Price / Cash	N/A	114.05	49.34	60.04
Price / Book	108.68	6.05	10.88	6.38
Net Income	-$51.06M	$179.69M	$3.59B	$331.87M
7 Day Performance	-1.37%	-1.68%	-0.26%	0.37%
1 Month Performance	3.43%	6.63%	4.52%	0.53%
1 Year Performance	96.10%	11.95%	29.17%	21.96%

Establishment Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ESTA Establishment Labs	1.2632 of 5 stars	$88.03 -0.8%	$89.71 +1.9%	+91.5%	$2.61B	$211.08M	N/A	1,004	Positive News Analyst Forecast
GKOS Glaukos	1.8222 of 5 stars	$147.30 -0.9%	$150.62 +2.3%	+43.2%	$8.67B	$507.44M	N/A	1,094	Analyst Forecast Insider Trade
LQDA Liquidia	2.8494 of 5 stars	$79.90 +0.9%	$68.88 -13.8%	+450.7%	$7.09B	$158.32M	569.60	50	Insider Trade
BLCO Bausch + Lomb	4.0045 of 5 stars	$17.13 +0.1%	$17.83 +4.1%	+14.4%	$6.12B	$5.10B	N/A	13,000	News Coverage Analyst Forecast
STVN Stevanato Group	2.7655 of 5 stars	€19.23 -0.3%	N/A	-24.5%	€5.83B	€1.20B	32.61	6,010

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ESTA) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Establishment Labs (ESTA) Competitors

ESTA vs. GKOS, LQDA, BLCO, STVN, and LIVN

How does Establishment Labs compare to Glaukos?

Summary

How does Establishment Labs compare to Liquidia?

Summary

How does Establishment Labs compare to Bausch + Lomb?

Summary

How does Establishment Labs compare to Stevanato Group?

Summary

How does Establishment Labs compare to LivaNova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESTA vs. The Competition

Establishment Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Establishment Labs (ESTA) Competitors

ESTA vs. GKOS, LQDA, BLCO, STVN, and LIVN

How does Establishment Labs compare to Glaukos?

Does the media refer more to ESTA or GKOS?

Which has better earnings and valuation, ESTA or GKOS?

Do analysts rate ESTA or GKOS?

Which has more volatility & risk, ESTA or GKOS?

Is ESTA or GKOS more profitable?

Do insiders & institutionals hold more shares of ESTA or GKOS?

Summary

How does Establishment Labs compare to Liquidia?

Which has better valuation and earnings, LQDA or ESTA?

Do analysts rate LQDA or ESTA?

Do insiders and institutionals have more ownership in LQDA or ESTA?

Which has more volatility and risk, LQDA or ESTA?

Does the media favor LQDA or ESTA?

Is LQDA or ESTA more profitable?

Summary

How does Establishment Labs compare to Bausch + Lomb?

Which has more volatility and risk, ESTA or BLCO?

Do analysts prefer ESTA or BLCO?

Do insiders & institutionals hold more shares of ESTA or BLCO?

Is ESTA or BLCO more profitable?

Does the media refer more to ESTA or BLCO?

Which has stronger valuation & earnings, ESTA or BLCO?

Summary

How does Establishment Labs compare to Stevanato Group?

Does the media refer more to STVN or ESTA?

Which has more volatility and risk, STVN or ESTA?

Do institutionals and insiders believe in STVN or ESTA?

Is STVN or ESTA more profitable?

Which has preferable valuation & earnings, STVN or ESTA?

Do analysts rate STVN or ESTA?

Summary

How does Establishment Labs compare to LivaNova?

Which has better valuation & earnings, LIVN or ESTA?

Does the media refer more to LIVN or ESTA?

Do institutionals and insiders have more ownership in LIVN or ESTA?

Is LIVN or ESTA more profitable?

Do analysts rate LIVN or ESTA?

Which has more risk & volatility, LIVN or ESTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESTA vs. The Competition

Establishment Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools